Long-Term Activity and Safety of a Low-Dose Hydrocortisone Tear Substitute in Patients with Dry Eye Disease-Reference-Cited by-同舟云学术

Long-Term Activity and Safety of a Low-Dose Hydrocortisone Tear Substitute in Patients with Dry Eye Disease

Published:2023-06-19 Issue:9 Volume:48 Page:799-804
ISSN:0271-3683
Container-title:Current Eye Research
language:en
Short-container-title:Current Eye Research

Author:

Rolando Maurizio¹,Villella Elena²,Loreggian Lara³,Marini Sara²,Loretelli Cristian³,Fiorina Paolo³⁴⁵,Barabino Stefano⁶^ORCID

Affiliation:

1. Ocular Surface Center, IS.Pre Oftalmica, Genoa, Italy

2. Department of Ophthalmology, ASST Fatebenefratelli SACCO-Università di Milano, Milan, Italy

3. International Center for T1D, Pediatric Clinical Research Center “Romeo ed Enrica Invernizzi”, Dipartimento di Scienze Biomediche e Cliniche, Università di Milano, Milan, Italy

4. Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA

5. Endocrinology Division, ASST Fatebenefratelli Sacco, Milan, Italy

6. Ocular Surface & Dry Eye Center, Department of Ophthalmology, ASST Fatebenefratelli SACCO, Università di Milano, Milan, Italy

Publisher

Informa UK Limited

Subject

Cellular and Molecular Neuroscience,Sensory Systems,Ophthalmology

Link

https://www.tandfonline.com/doi/pdf/10.1080/02713683.2023.2214948

Reference21 articles.

1. Innate and Adaptive Cell Populations Driving Inflammation in Dry Eye Disease

2. Defining Dry Eye from a Clinical Perspective

3. The negative effects of dry eye disease on quality of life and visual function

4. TFOS DEWS II Report Executive Summary

5. Updated definition and classification of dry eye disease: Renewed proposals using the nominal group and Delphi techniques

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dry Eye Para-Inflammation Treatment: Evaluation of a Novel Tear Substitute Containing Hyaluronic Acid and Low-Dose Hydrocortisone;Biomedicines;2023-12-11

2. Effectiveness of a New Active Tear Substitute Containing 0.2% Hyaluronic Acid and 0.001% Hydrocortisone on Signs and Symptoms of Dry Eye Disease by Means of Low- and High-Tech Assessments;Ophthalmology and Therapy;2023-11-10